Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon May 31, 2023 7:51pm
331 Views
Post# 35473886

Been an over correction, time to pile back

Been an over correction, time to pile back

Those who have been pilling out....time to start piling back in.
With only 2 days left before the up-to-date ASCO presentation. ( Saturday)
and
The pre- market KOL webinar, Monday, 
Mangement has pre- indicated to expect exceptional results, leading to expeditiously entering phase 3.
They aldo indicated not to expect a Business development deal, right away.
So after the KOL we will have more data/ results to " arm chair" analyze.
Taking things into early June.
People ( including myself), can analyze, predict, guess etc as to ONCs future.
Certian things are known.
1. They do have fast track approval for both MBc & pancreatic cancer treatment.
2. The early results shown last week, are in- line with the previous MBc study. 
3. The pancreatic cancer results with Roche tecentriq, were beyond expectations & lead to very quick fast track approval.
4. investors in general are tired of the wait & want a B.D. Deal ASAP ( management is well aware).
5. About 5-6 analysts have a " speculative buy" rating, with SP ranging from $3ps to $15ps. 
They all have one thing in common. A prediction of partnership announcement this calander year.
 

What we don't know:
1. The status of any discussions or negotiations with any company.
Anyone who claims to " know" either positive or negative outcomes is giving an opinion, not facts.

Regarding the share price as " being an indicator": see item #1, what we don't know.

I agree it has been a very long road. The SP went up from low $1.60s ( CDN) , to a spike of $3.00 in just about a month.
Funny ha ha, when the price was rising daily 10%, 15% etc....There was speculation of buyouts, partnerships.
Then profit taking, stock price retraction. Multitude of reasons.
And ...tthe chat room changes to name calling, doom & gloom, predictions of ONCs demise.
When in reality, not one of the numbered items above changed.
As I have said many times. Read through the " corporate presentation" first page of Onc web
Paints a very good picture.
Saturday & Monday, hopefully enough questions are answered to fill in some of the B.D. Blanks.
As of now, there is nothing to stop A.N. From proceeding with phase 3.
That would generate milestone payments to ONC.
Again, answers soon.

 

<< Previous
Bullboard Posts
Next >>